{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:43:20Z","timestamp":1790790200295,"version":"4.1.0"},"reference-count":30,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T00:00:00Z","timestamp":1634083200000},"content-version":"unspecified","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2021,9,23]]},"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive and fatal condition caused by deposition of transthyretin amyloid fibrils in the heart. This study aims to identify all patients diagnosed with ATTR-CM in Sweden, estimate the prevalence of ATTR-CM, describe patient characteristics and mortality, assess the importance of early symptoms (red flags) for identification of ATTR-CM, and compare with patients with heart failure (HF).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study combined multiple national health registers covering all specialist visits and prescriptions for the entire population of Sweden. Between January 2008 and December 2018, patients with ATTR-CM were identified retrospectively based on a combination of diagnosis codes and compared with matched, all-cause non-ATTR HF patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Overall, a total of 994 patients diagnosed with ATTR-CM were identified, with an average age at diagnosis of 73 years, and 30% of whom were female. The prevalence of diagnosed ATTR-CM cases in 2018 was 5.0 per 100\u2009000. The median survival from diagnosis was 37.6 months (CI 33.8 to 43.8), with a lower median survival in women (27.9 months, CI 23.3 to 33.8) compared with men (43.5 months, CI 37.6 to 49.6). Patients with ATTR-CM demonstrated reduced survival compared with patients with HF (p&lt;0.001). Compared with patients with HF, clinical identification of carpal tunnel syndrome, spinal stenosis, and atrioventricular and left bundle branch block can facilitate earlier diagnosis of ATTR-CM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study provides the first nationwide estimates of ATTR-CM prevalence and risk factors. The results reinforce the severity of the disease and the importance of earlier diagnosis, especially for female patients, in order to allow effective treatment and prevention of disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/openhrt-2021-001755","type":"journal-article","created":{"date-parts":[[2021,10,13]],"date-time":"2021-10-13T14:48:14Z","timestamp":1634136494000},"page":"e001755","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":43,"title":["Nationwide prevalence and characteristics of transthyretin amyloid cardiomyopathy in Sweden"],"prefix":"10.1136","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5776-6600","authenticated-orcid":false,"given":"Rosa Elisabeth","family":"Lauppe","sequence":"first","affiliation":[{"name":"Quantify Research AB, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3954-8914","authenticated-orcid":false,"given":"Johan","family":"Liseth Hansen","sequence":"additional","affiliation":[{"name":"Quantify Research AB, Stockholm, Sweden"},{"name":"Institute of Health and Society, University of Oslo Faculty of Medicine, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gerdesk\u00f6ld","sequence":"additional","affiliation":[{"name":"Pfizer Innovations AB, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H","family":"Rozenbaum","sequence":"additional","affiliation":[{"name":"Pfizer, Capelle a\/d IJssel, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Mette","family":"Strand","sequence":"additional","affiliation":[{"name":"Pfizer Denmark ApS, Ballerup, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merja","family":"Vakevainen","sequence":"additional","affiliation":[{"name":"Pfizer Oy, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6550-3176","authenticated-orcid":false,"given":"Johanna","family":"Kuusisto","sequence":"additional","affiliation":[{"name":"Department of Medicine and Clinical Research, Kuopio University Hospital and University of Eastern Finland, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einar","family":"Gude","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Gustafsson","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6285-9935","authenticated-orcid":false,"given":"J Gustav","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Wallenberg Center for Molecular Medicine and Lund University Diabetes Centre, Clinical Sciences, Lund University and Sk\u00e5ne University Hospital, Lund, Sweden"},{"name":"The Wallenberg Laboratory\/Department of Molecular and Clinical Medicine, Institute of Medicine, Gothenburg University and Sahlgrenska University Hospital, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,10,13]]},"reference":[{"key":"2025081710294320000_8.2.e001755.1","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev-med-052918-020140","article-title":"Cardiac amyloidosis: overlooked, underappreciated, and treatable","volume":"71","author":"Rubin","year":"2020","journal-title":"Annu Rev Med"},{"key":"2025081710294320000_8.2.e001755.2","doi-asserted-by":"publisher","DOI":"10.1136\/jmg.31.5.351"},{"key":"2025081710294320000_8.2.e001755.3","doi-asserted-by":"publisher","DOI":"10.1080\/13506120600876849"},{"key":"2025081710294320000_8.2.e001755.4","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.118.038169"},{"key":"2025081710294320000_8.2.e001755.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"2025081710294320000_8.2.e001755.6","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(19)33478-3"},{"key":"2025081710294320000_8.2.e001755.7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000098"},{"key":"2025081710294320000_8.2.e001755.8","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.102"},{"key":"2025081710294320000_8.2.e001755.9","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2025081710294320000_8.2.e001755.10","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2017.9236","article-title":"Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis","volume":"318","author":"Geller","year":"2017","journal-title":"JAMA"},{"key":"2025081710294320000_8.2.e001755.11","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"2025081710294320000_8.2.e001755.12","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1536\/ihj.15-005","article-title":"Contribution of electrocardiogram in the differentiation of cardiac amyloidosis and nonobstructive hypertrophic cardiomyopathy","volume":"56","author":"Huang","year":"2015","journal-title":"Int Heart J"},{"key":"2025081710294320000_8.2.e001755.13","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450"},{"key":"2025081710294320000_8.2.e001755.14","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1294"},{"key":"2025081710294320000_8.2.e001755.15","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-017-0316-1"},{"key":"2025081710294320000_8.2.e001755.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-008-0554-0"},{"key":"2025081710294320000_8.2.e001755.17","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199801000-00004"},{"key":"2025081710294320000_8.2.e001755.18","unstructured":"Garland A , Fransoo R , Olafson K . The epidemiology and outcomes of critical illness in Manitoba. Winnipeg, MB: Manitoba Centre for Health Policy, 2012."},{"key":"2025081710294320000_8.2.e001755.19","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407","article-title":"Epidemiology of cardiac amyloidosis\u2013associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States","volume":"12","author":"Gilstrap","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2025081710294320000_8.2.e001755.20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.024438"},{"key":"2025081710294320000_8.2.e001755.21","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40119-019-0142-5","article-title":"Estimating the prevalence of transthyretin amyloid cardiomyopathy in a large in-hospital database in Japan","volume":"8","author":"Winburn","year":"2019","journal-title":"Cardiol Ther"},{"key":"2025081710294320000_8.2.e001755.22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40119-020-00205-3","article-title":"Estimating the gender distribution of patients with wild-type transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis","volume":"10","author":"Kroi","year":"2021","journal-title":"Cardiol Ther"},{"key":"2025081710294320000_8.2.e001755.23","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10741-020-10010-8","article-title":"Transthyretin amyloid cardiomyopathy in women: frequency, characteristics, and diagnostic challenges","volume":"26","author":"Bruno","year":"2021","journal-title":"Heart Fail Rev"},{"key":"2025081710294320000_8.2.e001755.24","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"2025081710294320000_8.2.e001755.25","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1002\/ehf2.13110","article-title":"Prevalence of wild type transtyrethin cardiac amyloidosis in a heart failure clinic","volume":"8","author":"Lindmark","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2025081710294320000_8.2.e001755.26","doi-asserted-by":"crossref","unstructured":"Elliott P , Drachman BM , Gottlieb SS , et al . 1169 Interim analysis of data from a long-term, extension trial of tafamidis meglumine in patients with transthyretin amyloid cardiomyopathy. Eur Heart J 2019;40.doi:10.1093\/eurheartj\/ehz748.0011","DOI":"10.1093\/eurheartj\/ehz748.0011"},{"key":"2025081710294320000_8.2.e001755.27","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hft064"},{"key":"2025081710294320000_8.2.e001755.28","doi-asserted-by":"publisher","DOI":"10.1093\/eurjhf\/hfq121"},{"key":"2025081710294320000_8.2.e001755.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.596"},{"key":"2025081710294320000_8.2.e001755.30","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2011-301299"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2021-001755","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T17:29:55Z","timestamp":1755451795000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2021-001755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,10,13]]},"published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1136\/openhrt-2021-001755"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2021-001755","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]}}}